Fig. 3.

Fs vaccines combined with immune checkpoint inhibitors reduced tumor growth and incidence. a Percentage of tumor free mice. Mice were challenged, vaccinated and treated with checkpoint inhibitors (anti-PD-L1/ CTLA-4) as described in Fig. 1a. Mice were monitored for tumor incidence and tumor volume. Data are presented as percentage of tumor free mice and p values calculated using Log-rank (Mantel-Cox) Test. b Average 4 T1 tumor growth curves. Data were analyzed by Log-rank (Mantel-Cox) Test (***, p < 0.001). c Kaplan-Meyer survival curves of vaccinated mice. At 47–55 days post challenge, mice with tumor volume < 1000 mm³ and/or no clinical signs of illness were considered survivors. Data were analyzed using Log-rank (Mantel-Cox) Test. d Average 4 T1 tumor growth curves. The tumor volume of tumor bearing mice was measured and plotted for PC-FAST/ICI and NR-PCV/ICI, or Mock vaccinated mice. Data were analyzed by Log-rank (Mantel-Cox) Test (**, p < 0.01)